Scholarlink

<p>1-carbon (1&#xa0;C) metabolism is a key process required for nucleotide synthesis in activated lymphocytes and other immune-regulatory mechanisms. Commonly used and well-established drugs for the treatment of inflammatory disorders such as methotrexate and fluorouracil (5-FU) are known to interact with 1&#xa0;C metabolism And provide appreciable clinical benefit despite challenges with tolerance And patient compliance. Advances in our understanding of the enzymes involved in 1&#xa0;C metabolism coupled with differential expression highlights specific targeting of key enzymes may greatly enhance clinical efficacy And reduce side effect burden in comparison to the established therapies that are more indiscriminate in their mode of action. In recent years the methylenetetrahydrofolate dehydrogenase enzymes have gained increasing interest because of the role they play in 1&#xa0;C metabolism in the immune system and in progression of inflammatory diseases. High expression of these enzymes in activated immune cells and inflamed tissues coupled with chemical tractability provides compelling reasons to actively consider these enzymes as novel therapeutic targets.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The critical role of methylenetetrahydrofolate dehydrogenases in immune regulation and auto-immunity

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月14日

查看全文
  • Peter Bunyard,
  • Marina Makrecka-Kuka,
  • Laura McMillan

摘要

1-carbon (1 C) metabolism is a key process required for nucleotide synthesis in activated lymphocytes and other immune-regulatory mechanisms. Commonly used and well-established drugs for the treatment of inflammatory disorders such as methotrexate and fluorouracil (5-FU) are known to interact with 1 C metabolism And provide appreciable clinical benefit despite challenges with tolerance And patient compliance. Advances in our understanding of the enzymes involved in 1 C metabolism coupled with differential expression highlights specific targeting of key enzymes may greatly enhance clinical efficacy And reduce side effect burden in comparison to the established therapies that are more indiscriminate in their mode of action. In recent years the methylenetetrahydrofolate dehydrogenase enzymes have gained increasing interest because of the role they play in 1 C metabolism in the immune system and in progression of inflammatory diseases. High expression of these enzymes in activated immune cells and inflamed tissues coupled with chemical tractability provides compelling reasons to actively consider these enzymes as novel therapeutic targets.